KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Capital Expenditures (2016 - 2025)

Ionis Pharmaceuticals has reported Capital Expenditures over the past 17 years, most recently at -$29.7 million for Q4 2025.

  • Quarterly results put Capital Expenditures at -$29.7 million for Q4 2025, down 216.38% from a year ago — trailing twelve months through Dec 2025 was $478000.0 (down 98.94% YoY), and the annual figure for FY2025 was $478000.0, down 98.94%.
  • Capital Expenditures for Q4 2025 was -$29.7 million at Ionis Pharmaceuticals, down from $5.3 million in the prior quarter.
  • Over the last five years, Capital Expenditures for IONS hit a ceiling of $25.5 million in Q4 2024 and a floor of -$29.7 million in Q4 2025.
  • Median Capital Expenditures over the past 5 years was $4.4 million (2021), compared with a mean of $4.9 million.
  • Biggest five-year swings in Capital Expenditures: surged 3213.19% in 2024 and later plummeted 216.38% in 2025.
  • Ionis Pharmaceuticals' Capital Expenditures stood at $2.5 million in 2021, then surged by 65.43% to $4.1 million in 2022, then plummeted by 119.79% to -$819000.0 in 2023, then surged by 3213.19% to $25.5 million in 2024, then plummeted by 216.38% to -$29.7 million in 2025.
  • The last three reported values for Capital Expenditures were -$29.7 million (Q4 2025), $5.3 million (Q3 2025), and $12.3 million (Q2 2025) per Business Quant data.